All In Biotech

Drug Trial Radar · NCT02033707

Effects of Hallucinogens and Other Drugs on Mood and Performance

Phase I Study Characterizing Effects of Hallucinogens and Other Drugs on Mood and Performance

Last checked: Nov 20, 2026Latest source record: May 16, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

20

Actual

Start

Apr 2014

Primary completion

Feb 2019

Study completion Feb 2019

Sponsor

Lead sponsor
Johns Hopkins UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 13, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Basic science
Who can join
All sexes, from 21 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This non-treatment study will investigate the effects on mood and performance caused by hallucinogens and other psychoactive compounds.

Conditions

  • Healthy

Interventions

  • Hallucinogens and psychoactive substancesDrug

    One of the following or placebo will be given: Hallucinogens: DMT, 4-phosphoryloloxy-N-diethyltryptamine, dipropyltryptamine (DPT), ketamine, dextromethorphan, mescaline, PCP, psilocybin, salvinorin-A, LSD, d-lysergic acid amide (LSA), MDMA, cannabis Sedatives/anxiolytics: alprazolam, diazepam, lorazepam, secobarbital, temazepam, triazolam, zolpidem Antihistamines: diphenhydramine, chlorpheniramine Stimulants: d-amphetamine, caffeine, ephedrine, methylphenidate, diethylproprion Opioids: heroin, morphine, oxycodone, hydrocodone, methadone, codeine Other: alcohol, scopolamine, nicotine Each volunteer will receive a hallucinogen on at least one of five sessions. More drugs are listed than will be administered to increase the degree to which volunteers are "blind" to the drugs being studied. It is important that the volunteer and research staff be blinded to specific drug conditions to minimize confounding the results with expectations about the nature of drug effects.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rating of "Drug Liking" on the End of Day QuestionnaireTime frame: Completed at the end of the experimental session (approximately 8 hours after capsule administration)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Behavioral Pharmacology Research Unit, Johns Hopkins Bayview Medical Center

    Baltimore, Maryland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.